Technical Analysis for ALNY - Alnylam Pharmaceuticals, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
F | 143.31 | -0.28% | -0.40 |
Earnings due: May 2
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
New 52 Week Closing Low | Bearish | 0.00% | |
Slingshot Bearish | Bearish Swing Setup | 0.00% | |
Down 3 Days in a Row | Weakness | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
New 52 Week Closing Low | Bearish | -0.28% | |
New 52 Week Low | Weakness | -0.28% | |
Oversold Stochastic | Weakness | -0.28% | |
New 52 Week Closing Low | Bearish | -0.34% | |
Oversold Stochastic | Weakness | -0.34% | |
20 DMA Resistance | Bearish | -1.89% |
Alert | Time |
---|---|
60 Minute Opening Range Breakout | about 21 hours ago |
Rose Above Previous Day's High | about 21 hours ago |
10 DMA Resistance | about 22 hours ago |
Rose Above 10 DMA | about 22 hours ago |
Up 1% | about 22 hours ago |
Get a Trading Assistant
- Earnings date: 05/02/2024
Alnylam Pharmaceuticals, Inc. Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and commercializing novel therapeutics based on RNA interference (RNAi). Its principal programs under clinical or pre-clinical development include ALN-TTR comprising ALN-TTR02 and ALN-TTRsc for the treatment of transthyretin-mediated amyloidosis; ALN-AT3 for the treatment of hemophilia and rare bleeding disorders; ALN-AS1 for the treatment of acute intermittent porphyria; ALN-PCS for the treatment of hypercholesterolemia; and ALN-TMP for the treatment of hemoglobinopathies, including beta-thalassemia. The company's early stage program comprise ALN-AAT, an RNAi therapeutic targeting the mutant Z-allele in alpha-1-antitrypsin deficiency (AAT deficiency) for the treatment of AAT deficiency-associated liver disease. It also has two partner-based programs in clinical development, including ALN-RSV01 for the treatment of respiratory syncytial virus infection; and ALN-VSP for the treatment of liver cancers, as well as one candidate in pre-clinical development comprising ALN-HTT for the treatment of Huntington's disease. The company has strategic alliances with F. Hoffmann-La Roche Ltd; Arrowhead Research Corporation; Takeda Pharmaceutical Company Limited; Monsanto Company; Isis Pharmaceuticals, Inc.; Novartis Pharma AG; Medtronic, Inc.; Kyowa Hakko Kirin Co., Ltd.; Genzyme Corporation; The Medicines Company; Cubist Pharmaceuticals, Inc; Biogen Idec Inc.; and Ascletis Pharmaceuticals (Hangzhou) Co., Ltd. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Clinical Development Cholesterol Liver Disease Amyloid Amyloidosis Huntington's Disease Hemoglobin Hemophilia Antitrypsin Deficiency Hypercholesterolemia Spinal Muscular Atrophy Genzyme Rna Interference Alnylam Pharmaceuticals Deficiency Hemophilia A Liver Cancer Thalassemia Therapeutic Gene Modulation Transthyretin Treatment Of Hemophilia Medtronic Acute Intermittent Porphyria Alpha 1 Antitrypsin Deficiency Beta Thalassemia Hemoglobinopathies Monsanto
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 218.88 |
52 Week Low | 141.975 |
Average Volume | 837,731 |
200-Day Moving Average | 172.71 |
50-Day Moving Average | 150.17 |
20-Day Moving Average | 148.86 |
10-Day Moving Average | 145.20 |
Average True Range | 3.90 |
RSI (14) | 35.06 |
ADX | 15.94 |
+DI | 16.39 |
-DI | 23.19 |
Chandelier Exit (Long, 3 ATRs) | 147.64 |
Chandelier Exit (Short, 3 ATRs) | 153.68 |
Upper Bollinger Bands | 157.03 |
Lower Bollinger Band | 140.69 |
Percent B (%b) | 0.16 |
BandWidth | 10.98 |
MACD Line | -2.45 |
MACD Signal Line | -2.05 |
MACD Histogram | -0.4049 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 147.91 | ||||
Resistance 3 (R3) | 148.32 | 147.19 | 147.14 | ||
Resistance 2 (R2) | 147.19 | 146.02 | 146.99 | 146.89 | |
Resistance 1 (R1) | 145.25 | 145.30 | 144.69 | 144.84 | 146.63 |
Pivot Point | 144.13 | 144.13 | 143.84 | 143.92 | 144.13 |
Support 1 (S1) | 142.19 | 142.95 | 141.62 | 141.78 | 139.99 |
Support 2 (S2) | 141.06 | 142.23 | 140.86 | 139.73 | |
Support 3 (S3) | 139.12 | 141.06 | 139.48 | ||
Support 4 (S4) | 138.71 |